About this trial
The purpose of this study is to evaluate the efficacy, safety and economic benefits of Cyclical Pressure Topical Wound Oxygen (TWO2) Therapy in the treatment of venous leg ulcers. Participants will utilize standard of care (SOC) multilayer compression dressings with an inactive wound contact layer. Following a 2-week run-in period with SOC and after meeting all eligibility criteria, subjects will be randomized in a 1:1 ratio with TWO2 therapy or sham control therapy plus SOC. Participants will enter the intervention period of up to 16-weeks, followed by a long-term follow-up period of 52 weeks post randomization.
Eligibility criteria
Qualifiers
Adults ≥ 18 years and able to provide written informed consent
Patients who have a chronic venous leg ulcer (VLU) below the knee at or above the malleolus determined to be due to underlying venous disease
Venous reflux ≥ 500 mil sec/superficial or 1 sec/deep or venous mapping after interventions following a vascular procedure
VLU of ≥ 1.5cm2 and ≤ 50cm2 after debridement at study enrolment i.e. Screening visit
Disqualifiers
• Known allergy to any of the protocol-stipulated treatments, or non-tolerance of multilayer, multicomponent compression therapy
Acute thrombophlebitis or Deep Vein Thrombosis (DVT) and within three months preceding study entry
Subject awaiting venous ablation or is less than 30 days post ablation
Surgery during three months prior to study entry (such as abdominal, gynecological, hip or knee replacement)
Trial design
Treatments tested in this trial
- Topical Wound Oxygen Therapy
- Sham Control Topical Wound Oxygen